Literature DB >> 1873592

Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.

K Doney1, L D Fisher, F R Appelbaum, C D Buckner, R Storb, J Singer, A Fefer, C Anasetti, P Beatty, W Bensinger.   

Abstract

Between February 1972 and December 1987, 192 adults (greater than or equal to 18 years old) with acute lymphoblastic leukemia were transplanted using genotypically HLA-identical marrow donors. Median patient age was 23 years. Eighty-nine patients were in marrow remission and 103 were in relapse. Conditioning regimens included chemotherapy alone (three patients) or in combination with 9.2-17.5 Gy total body irradiation (189 patients). Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate and/or cyclosporine. Seventy-nine patients developed grades II-IV acute GVHD and 28 of 122 patients who survived at least 100 days developed chronic GVHD. Relapse-free survival at 5 years was 21% for patients transplanted in first remission, 15% for those in greater than or equal to 2nd remission, and 12% for those transplanted in relapse. Patient and donor characteristics were evaluated in multivariate analyses for their effect on development of acute GVHD, survival, relapse, and relapse-free survival. An increased risk of developing acute GVHD was associated with increasing donor age. Variables significantly associated with both increased survival and relapse-free survival included transplantation in first remission, younger patient age, and not developing interstitial pneumonia. A decreased probability of relapse was associated with transplantation in first remission, male patient sex, and grades II-IV acute GVHD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873592

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia.

Authors:  Akio Shigematsu; Junji Tanaka; Ritsuro Suzuki; Yoshiko Atsuta; Takakazu Kawase; Yoichi M Ito; Takuya Yamashita; Takahiro Fukuda; Keiki Kumano; Koji Iwato; Fumiaki Yoshiba; Heiwa Kanamori; Naoki Kobayashi; Takashi Fukuhara; Yasuo Morishima; Masahiro Imamura
Journal:  Int J Hematol       Date:  2011-11-01       Impact factor: 2.490

Review 3.  Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.

Authors:  Samer K Khaled; Sandra H Thomas; Stephen J Forman
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

4.  Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

Authors:  Prajwal Dhakal; Jasleen Kaur; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Leuk Lymphoma       Date:  2019-07-18

Review 5.  Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?

Authors:  Stephen J Forman
Journal:  Best Pract Res Clin Haematol       Date:  2009-12       Impact factor: 3.020

Review 6.  Bone marrow transplantation for acute lymphoblastic leukemia (ALL).

Authors:  H M Lazarus; J M Rowe
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

7.  Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.

Authors:  Jutta Auberger; Johannes Clausen; Wolfgang Willenbacher; Martin Erdel; Eberhard Gunsilius; Andreas Petzer; Günther Gastl; David Nachbaur
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

8.  Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

Authors:  Anthony S Stein; Joycelynne M Palmer; Margaret R O'Donnell; Neil M Kogut; Ricardo T Spielberger; Marilyn L Slovak; Ni-Chun Tsai; David Senitzer; David S Snyder; Sandra H Thomas; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-11       Impact factor: 5.742

Review 9.  Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Partow Kebriaei
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

Review 10.  Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.

Authors:  P Vandenberghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.